CTLA4 and cancer: While the clinical breakthrough of immune checkpoint inhibitors such as anti-programmed death-1 (PD-1) or cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) in certain cancers has fueled optimism in immunotherapy, the efficacy is limited to a small subset of patients.